GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...

Asthma is a chronic inflammatory disease that affects the lungs. In a child with asthma, the airways are very sensitive, ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

Blue Cross Blue Shield company Health Care Service Corporation is limiting access for in-office administration of asthma ...

Although cost-related asthma treatment nonadherence has declined in the US, nearly 1 in 6 patients are still nonadherent due to cost concerns.

"Thankfully, asthma nowadays is a much more manageable disease with good outcomes than it used to be," offers Burkhardt. "But it does require persistence and lifelong treatment in many cases." ...

LONDON - GSK plc (LSE/NYSE: GSK) has announced the acceptance of regulatory filings in China and Japan for depemokimab, a new biologic treatment for asthma with type 2 inflammation and chronic ...

Members of the team plan to study hundreds or thousands of patients to understand who has the highest cAMP levels and how ...

Arterial-Blood Studies during Treatment of Severe Refractory Bronchial Asthma in Case 2 on May 17, after Theophylline and Epinephrine (1), at 8:00 A.M., when the Asthma Was Refractory to ...